About Incyte. Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs for oncology, inflammation and diabetes. Incyte’s most advanced compound, INCB18424, is in Phase III development for myelofibrosis. For additional information on Incyte, visit the Company's web site at ▇▇▇.▇▇▇▇▇▇.▇▇▇.
Appears in 2 contracts
Sources: License, Development and Commercialization Agreement (Incyte Corp), Collaboration and License Agreement (Incyte Corp)
About Incyte. Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs for oncology, inflammation and diabetes. Incyte’s most advanced compound, INCB18424, is in Phase III development for myelofibrosis. For additional information on Incyte, visit the Company's ’s web site at ▇▇▇.▇▇▇▇▇▇.▇▇▇.
Appears in 2 contracts
Sources: Collaboration and License Agreement (Incyte Corp), License, Development and Commercialization Agreement (Incyte Corp)
About Incyte. Incyte Corporation is a Wilmington, Delaware-based drug discovery and development biopharmaceutical company focused on developing the discovery, development and commercialization of proprietary small molecule drugs drugs, primarily for oncology, inflammation and diabetes. Incyte’s most advanced compound, INCB18424, is in Phase III development for myelofibrosis. For additional information on Incyte, please visit the Company's web site website at ▇▇▇.▇▇▇▇▇▇.▇▇▇.
Appears in 1 contract
Sources: License, Development and Commercialization Agreement (Agenus Inc)